Orasis Pharmaceuticals is developing a corrective eye drop to treat presbyopia as an alternative to reading glasses
what is presbyopia
Presbyopia, the inability to focus on close objects, is common after age 40 and affects more then 1.8 billion people worldwide. Current treatment options are either cumbersome or invasive, presenting a significant unmet need for quality of life improvement for people with presbyopia.
our solution
CSF-1 is an eye drop currently in clinical development to treat presbyopia.
Delivered as a topical solution directly to the eyes, CSF-1 contains a proprietary combination of existing and well-known components with the potential to restore vision in people with presbyopia.
company updates
Apr 8 2019
CEO Elad Kedar Discusses Our Ongoing Phase 2b Clinical Study of CSF-1 and the Eye Drop’s Treatment Effect with Healio
Mar 27 2019
Orasis Announces Initiation of Phase 2b Clinical Study of CSF-1 for the Treatment of Presbyopia
Nov 27 2018
Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Board
Oct 22 2018